Skip to main content
Premium Trial:

Request an Annual Quote

EMBL Raises 10M Euros for New Technology Fund

NEW YORK, Dec. 10 – The European Molecular Biology Laboratory has raised 10 million euros ($8.9 million) for its first technology fund, which will look to invest in start up companies emerging from the research center. 

The European Molecular Biology Laboratory Enterprise Management fund, or EMBLEM, received funds from investors including  3i of the UK, BankInvest of Denmark, and Marco Polo of Spain. 

EMBL hopes to raise an additional seven million euros and to close the fund next year. 

EMBL, which has spun off such companies as Lion Bioscience, Cenix BioScience, Cellzome, and Gene Bridges, hopes that the new fund will help it to commercialize more emerging technologies. 

“With the EMBL Technology Fund we have created another vital building block necessary for the successful overall implementation of technology transfer at EMBL,” Gabor Lamm, managing director of EMBLEM, said in a statement released last week.

EMBL of Heidelberg, Germany, is a basic research institute. It receives its funding from 16 member states, including most of the EU, Switzerland, and Israel.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.